Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders

Journal of Psychosomatic Research

Volumn 62, Issue 3, 2007, Pages 349-355

  Dell'Osso, Liliana ^a   Pini, Stefano ^a   Maggi, Luca ^a   Rucci, Paola ^a   Del Debbio, Alessandro ^a   Carlini, Marina ^a   Baldini, Alessia ^a   Ferrari, Giuseppe ^c   Manca, Elena ^a   Beverini, Enrico ^c   Amore, Mario ^d   Scarallo, Vincenzo ^b   Semeraro, Quirico ^b   Brunetto, Maurizia ^e   Bonino, Ferruccio ^f   Maj, Mario ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e UNIVERSITY HOSPITAL OF PISA   (Italy)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Depression; HCV+ patients; Interferon treatment; Subthreshold mania

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANAMNESIS; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOMANIA; MAJOR DEPRESSION; MALE; MANIA; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SELF REPORT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; INTERFERON-ALPHA; MALE; MIDDLE AGED; PILOT PROJECTS; RIBAVIRIN; RISK FACTORS; STATISTICS;

EID: 33847136351     PISSN: 00223999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2006.10.024     Document Type: Article

References (27)

1. Crone C., and Gabriel G. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract 9 (2003) 93-110
2. Valentine A., and Meyers C. Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep 7 (2005) 391-395
3. Constant A., Castera L., Dantzer R., Couzigou P., de Ledinghen V., Demotes-Mainard J., and Henry C. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 66 (2005) 1050-1057
4. Manns M., Mc Hutchison J., Gordon S., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 (2001) 958-965
5. Fried M., Shiffman M., Reddy K., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
6. Bonaccorso S., Marino V., Puzella A., et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alfa based immunotherapy are related to interferon-alfa-induced changes in the serotonergic system. J Clin Psychopharmacol 22 (2002) 86-90
7. Pariante C., Orru M., Baita A., Farci M., and Carpiniello B. Treatment with interferon-alfa in patients with chronic hepatitis and mood or anxiety disorders. Lancet 354 (1999) 131-132
8. Ho S., Nguyen H., Tetrick L., Opitz G., Basara M., and Dieperink E. Influence of psychiatric diagnoses on interferon-alfa treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 96 (2001) 157-164
9. Dieperink E., Willenbring M., and Ho S. Neuropsychiatric symptoms associated with hepatitis C and interferon alfa: a review. Am J Psychiatry 157 (2000) 867-876
10. Judd L., and Akiskal H. The prevalence and disability of bipolar spectrum disorders in the US population: reanalysis of the ECA database taking into account subthreshold cases. J Affect Disord 73 (2003) 123-131
11. Akiskal H., Maser J., Zeller P., Endicott J., Coryell W., Keller M., Warshaw M., Clayton P., and Goodwin F. Switching from 'unipolar' to bipolar: II. An 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry 52 (1995) 114-123
12. Bech P., Bolwig T., Kramp P., and Rafaelsen O. The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale. Acta Psychiatr Scand 59 (1979) 420-430
13. Dell'Osso L., Armani A., Rucci P., Frank E., Fagiolini A., Corretti G., Shear M., Grochocinski V., Maser J., Endicott J., and Cassano G. Measuring mood spectrum: comparison of interview (SCI-MOODS) and self-report (MOODS-SR) instruments. Compr Psychiatry 43 (2002) 69-73
14. Cassano G., Rucci P., Frank E., Fagiolini A., Dell'Osso L., Shear M., and Kupfer D. The mood spectrum in unipolar and bipolar disorder: arguments for a unitary approach. Am J Psychiatry 161 (2004) 1264-1269
15. Golden J., O'dwyer A., and Conroy R. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 27 (2005) 431-438
16. First M., Spitzer R., Williams J., and Gibbon M. Structured Clinical Interview for DSM-IV-patient edition (SCID-P) (1995), American Psychiatric Press, Washington, DC
17. Overall J., and Gorham D. The Brief Psychiatric Rating Scale. Psychol Rep 10 (1962) 799-812
18. Guy W. ECDEU assessment manual for psychopharmacology, revised (1976), US Department of Health, Education and Welfare, Rockville, MD
19. Bech P., and Rafaelsen O. The use of rating scales exemplified by a comparison of the Hamilton and the Bech-Rafaelsen Melancholia Scale. Acta Psychiatr Scand 62 Suppl 285 (1980) 128-132
20. Spielberger C., Gorsuch R., Lushene R., Vagg P., and Jacobs G. Manual for the State-Trait Anxiety Inventory (Form Y) (1983), Consulting Psychologists Press, Palo Alto, CA
21. Fagiolini A., Dell'Osso L., Pini S., Armani A., Bouanani S., Rucci P., Cassano G., Endicott J., Maser J., Shear M., Grochocinski V., and Frank E. Validity and reliability of a new instrument for assessing mood symptomatology: the Structured Clinical Interview for Mood Spectrum (SCI-MOODS). Int J Methods Psychiatr Res 8 (1999) 71-82
22. Raison C., Demetrashvili M., Capuron L., and Miller A. Neuropsychiatric adverse effects of interferon-alfa: recognition and management. CNS Drugs 19 (2005) 105-123
23. Constant A., Castera L., Quintard B., Bernard P., de Ledinghen V., Couzigou P., and Bruchon-Schweitzer M. Psychosocial factors associated with perceived disease severity in patients with chronic hepatitis C: relationship with information sources and attentional coping styles. Psychosomatics 46 (2005) 25-33
24. Trask P., Esper P., Riba M., and Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 18 (2000) 2316-2326
25. Dieperink E., Ho S., Thuras P., and Willenbring M. A prospective study of neuropsychiatric symptoms associated with interferon-α-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 44 (2003) 104-112
26. Raison C., Borisov A., Broadwell S., Capuron L., Woolwine B., Jacobson I., Nemeroff C., and Miller A. Depression during pegylated interferon-alfa plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 66 (2005) 41-48
27. Kraus M., Shäfer A., Al-Taie O., and Scheurlen M. Prophylactic SSRI during interferon alfa re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepatitis 12 (2005) 96-100